# Drug of interest
My drug of interest is moxifloxacin.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. UGT1A1 (z: 33.15)
2. UGT1A8 (z: 7.36)
3. UGT1A10 (z: 4.26)
4. ABCB1 (z: 4.08)
5. UGT1A5 (z: 4.05)
6. UGT1A7 (z: 3.94)
7. UGT1A3 (z: 3.94)
8. UGT1A4 (z: 3.81)
9. UGT1A9 (z: 3.78)
10. UGT1A6 (z: 3.4)
11. ABCC2 (z: 2.34)
12. G6PD (z: 2.09)
13. UGT2B4 (z: 1.81)
14. ABCG2 (z: 1.58)
15. CYP2D6 (z: 1.11)
16. UGT2A1 (z: 0.98)
17. CBR1 (z: 0.94)
18. ABCC1 (z: 0.92)
19. ABCB4 (z: 0.9)
20. ABCC4 (z: 0.89)
21. CYP2S1 (z: 0.87)
22. UGT2B28 (z: 0.83)
23. UGT2B11 (z: 0.82)
24. CYP2C19 (z: 0.77)
25. CBR3 (z: 0.76)
26. UGT2B7 (z: 0.76)
27. UGT2B15 (z: 0.74)
28. CYP2D7 (z: 0.73)
29. UGT2B10 (z: 0.73)
30. SLC22A1 (z: 0.71)
31. ABCC5 (z: 0.68)
32. SLCO1B1 (z: 0.63)
33. UGT2B17 (z: 0.61)
34. CYP1A2 (z: 0.54)
35. DCK (z: 0.46)
36. NR1I2 (z: 0.43)
37. RUNDC3B (z: 0.38)
38. CYP26C1 (z: 0.38)
39. COMT (z: 0.38)
40. NQO2 (z: 0.37)
41. MROH2A (z: 0.35)
42. ABCC3 (z: 0.34)
43. FMO5 (z: 0.33)
44. GSTA3 (z: 0.33)
45. CYP3A4 (z: 0.33)
46. ABCC11 (z: 0.31)
47. SULT1E1 (z: 0.31)
48. ABCC10 (z: 0.31)
49. SLC22A16 (z: 0.3)
50. ABCB6 (z: 0.3)

# Known pharmacogenetic associations
In addition, please consider that the following pharmacogenetic interactions are already known for this drug, according to PharmGKB:
- UGT1A1

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**moxifloxacin**: Moxifloxacin's metabolism primarily occurs via glucuronide and sulfate conjugation involving the UGT gene family (UGT1A1, UGT1A5, UGT1A9, UGT1A8, UGT1A4, UGT1A3, UGT1A6, UGT1A10), and variants in these genes can affect the drug’s pharmacokinetics such as metabolism and excretion. Additionally, the ABCB1 gene, coding for P-glycoprotein, influences moxifloxacin’s absorption and elimination, while G6PD relates to oxidative stress response, and CYP1A2 has a minor role in its pharmacokinetics.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**UGT1A1**: UGT1A1 plays a critical role in drug metabolism primarily through glucuronidation, affecting both pharmacokinetics and pharmacodynamics. For example, the gene’s variations, like UGT1A1*28, reduce the clearance of drugs such as irinotecan's active metabolite SN-38, leading to severe side effects and requiring dosage adjustments. Similarly, UGT1A1 influences the metabolism of HIV drugs like atazanavir and indinavir, impacting their effectiveness and concentration in the body. This gene also affects the metabolism of other medications such as atorvastatin, impacting treatments across various therapeutic areas like cancer and lipid management.

**UGT1A8**: UGT1A8 plays a crucial role in the metabolism of drugs such as atorvastatin, axitinib, valproic acid, methotrexate, and raloxifene by catalyzing their glucuronidation, leading to the formation of water-soluble glucuronide conjugates that facilitate drug excretion. Variants in the UGT1A8 gene can modify the activity of the enzyme, thereby affecting the concentration, efficacy, and toxicity of these drugs, with notable effects on drugs like irinotecan, where altered metabolism significantly impacts its toxicity profile.

**UGT1A10**: UGT1A10 is involved in the metabolism of drugs like atorvastatin, axitinib, valproic acid, methotrexate, and irinotecan through glucuronidation, impacting their bioavailability, elimination, and therapeutic levels. This enzyme's activity variances can alter drug efficacy and side effect profiles, making the personalization of dosages based on genetic makeup imperative for optimizing therapeutic outcomes and minimizing adverse effects.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**UGT1A5**: UGT1A5 plays a crucial role in the glucuronidation process that affects the metabolism, efficacy, and side effects of certain medications, such as the statins atorvastatin and simvastatin, the anticonvulsant valproic acid, and the chemotherapeutic agent methotrexate. Variations in the activity of UGT1A5 can influence the clearance and toxicity of these drugs, impacting their therapeutic usefulness and safety.

**UGT1A7**: UGT1A7, an enzyme involved in drug metabolism, significantly influences the effectiveness and safety of drugs such as atorvastatin, axitinib, valproic acid, and methotrexate by affecting their clearance and plasma levels. Variations in UGT1A7 activity can lead to diverse therapeutic outcomes and adverse effects, like muscle and liver toxicity, by altering the metabolism of these drugs, indicating the need for careful consideration of UGT1A7 variability in drug prescription and therapy management.

**UGT1A3**: Variations in the UGT1A3 gene, critical for the glucuronidation process, influence the metabolism and clinical effects of drugs such as atorvastatin, deferasirox, telmisartan, valproic acid, methotrexate, and montelukast. These interactions can alter drug clearance, efficacy, side effects, and toxicity, highlighting the importance of considering genetic factors in drug dosing and therapy optimization.

**UGT1A4**: UGT1A4 catalyzes the glucuronidation of drugs such as lamotrigine, atorvastatin, valproic acid, methotrexate, testosterone, tamoxifen, anastrozole, olanzapine, and n-desmethylclozapine, affecting their solubility, detoxification, and excretion. Genetic variations in UGT1A4 can significantly alter the metabolism of these drugs, including lamotrigine and hormonal treatments like testosterone and tamoxifen, impacting their therapeutic effectiveness and risk of toxicity, which is crucial for managing conditions ranging from epilepsy and cholesterol to hormone-sensitive disorders and psychiatric conditions.

**UGT1A9**: UGT1A9 plays a key role in the glucuronidation and metabolism of various drugs, including NSAIDs like diclofenac, antiretrovirals, and chemotherapy agents like irinotecan. Genetic variations in UGT1A9 can significantly influence the pharmacokinetics and pharmacodynamics of these drugs, affecting their efficacy and the severity of side effects such as neutropenia, particularly evident in treatments involving mycophenolic acid and irinotecan.

**UGT1A6**: UGT1A6 is a key enzyme involved in the metabolism of several drugs through glucuronidation, influencing their solubility and excretion. Specific genetic variants of UGT1A6 can alter the metabolism and effectiveness of drugs like atorvastatin and acetaminophen, potentially affecting their efficacy and toxicity. Additionally, it processes drugs such as valproic acid, methotrexate, aspirin, and other NSAIDs, where genetic differences can impact drug levels, exposure, and side effect profiles, playing a significant role in pharmacokinetics and potentially pharmacodynamics.

**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**UGT2B4**: The UGT2B4 gene is crucial in the metabolism and excretion of nonsteroidal anti-inflammatory drugs (NSAIDs) by converting them into water-soluble glucuronide conjugates, impacting their clearance and action duration. Variations in this gene affect the drug levels in the body, influencing the efficacy and safety of NSAID treatments, potentially leading to reduced effectiveness or an increased risk of adverse effects like gastrointestinal bleeding.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**UGT2A1**: UGT2A1, a gene in the UDP-glucuronosyltransferase family involved in detoxification, might influence the pharmacokinetics of drugs like imatinib, which is metabolized through glucuronidation by related enzymes. Although there is no direct evidence linking UGT2A1 with imatinib, variations in UGT2A1 could potentially affect imatinib's metabolism, efficacy, and toxicity, even if the exact relationship remains speculative and unconfirmed.

**CBR1**: CBR1 notably affects the metabolism of chemotherapeutic drugs such as doxorubicin and daunorubicin by reducing them into less active compounds like doxorubicinol, thereby potentially altering their effectiveness and toxicity, particularly influencing cardiotoxicity risks. Genetic variants in CBR1 can lead to varied metabolism rates, impacting drug plasma levels and toxicity, while its interactions with other drugs like fluorouracil and cyclophosphamide, though less definitively understood, suggest modifications in drug efficacy and safety through carbonyl reduction.

**ABCC1**: ABCC1, a critical gene encoding for an efflux transporter, significantly affects the pharmacokinetics and pharmacodynamics of various drugs by impacting their absorption, distribution, and elimination. Notably, it modulates the clearance of anticancer drugs like SN-38 and doxorubicin from cells, contributing to drug resistance and variability in therapeutic efficacy and toxicity, which is particularly relevant in optimizing cancer chemotherapy. Other drugs such as vincristine, methotrexate, and ritonavir, among others, also demonstrate pharmacogenetic interactions with ABCC1, affecting treatment outcomes especially in oncology.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**ABCC4**: ABCC4 gene variants influence the pharmacokinetics and efficacy of various drugs by modulating their efflux from cells, which impacts drug concentrations in the body. This gene affects a wide range of drugs including cancer treatments (doxorubicin, methotrexate), antiretrovirals (zidovudine, tenofovir), and medications used in cardiovascular diseases and immune disorders (clopidogrel, azathioprine), potentially leading to variable therapy outcomes and drug resistance.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**UGT2B28**: UGT2B28 is involved in the glucuronidation process that helps in the elimination of drugs and hormones from the body, influencing the pharmacokinetics of hormone-based therapies used in treating hormone-dependent cancers. The gene's polymorphisms primarily affect drug metabolism rates, leading to variations in treatment outcomes or adverse effects due to differences in drug clearance rates.

**UGT2B11**: UGT2B11 is involved in the metabolism of drugs and hormones through glucuronidation, impacting their efficacy and toxicity by altering drug solubility and excretion. This enzyme plays a critical role in the pharmacokinetics of potentially estrogen or androgen-targeted therapies and other drugs requiring glucuronidation, like certain pain medications or anti-inflammatories, affecting how quickly they are metabolized and eliminated from the body.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**CBR3**: CBR3, an enzyme involved in metabolizing drugs by reducing carbonyl groups to alcohols, significantly influences the pharmacokinetics of the chemotherapy drug doxorubicin, altering its efficacy and toxicity due to genetic variations such as CBR3 V244M. This variation affects how different individuals process doxorubicin, potentially necessitating customized dosage adjustments. Furthermore, CBR3 might interact similarly with other chemotherapy agents like docetaxel and paclitaxel, impacting their plasma concentrations and therapeutic effects.

**UGT2B7**: UGT2B7 is crucial in the metabolism and clearance of various drugs, including opioids like morphine and buprenorphine, antiretrovirals such as zidovudine, antiepileptics like valproic acid, cardiovascular drugs, and NSAIDs among others, influencing their efficacy, side effects, and toxicity. Genetic variability in UGT2B7 can significantly impact the pharmacokinetics and therapeutic outcomes of these drugs, which may require personalized dosing to optimize benefits and minimize adverse reactions.

**UGT2B15**: UGT2B15 is an enzyme involved in the metabolism of numerous drugs including lorazepam, oxazepam, acetaminophen, and lamotrigine, primarily through the process of glucuronidation which aids in their excretion. Genetic variants in UGT2B15 can alter enzyme activity, impacting the effectiveness and toxicity of these drugs by affecting their plasma concentrations and systemic availability.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**UGT2B10**: UGT2B10, a key enzyme in the glucuronidation pathway, influences the metabolism, clearance, and effects of drugs such as nicotine, cotinine, clozapine, and possibly olanzapine. Variants in the UGT2B10 gene affect the efficacy and toxicity of these substances by altering their pharmacokinetics, which necessitates consideration for dosage adjustments and careful monitoring in clinical settings based on an individual's genetic makeup.

**SLC22A1**: The gene SLC22A1, encoding for the organic cation transporter 1 (OCT1), significantly influences the absorption and distribution of various drugs, such as metformin, tramadol, lamotrigine, ondansetron, rasagiline, and imatinib, by affecting their hepatic uptake. Genetic variations in SLC22A1 can lead to different efficacy and safety profiles for these drugs, necessitating potential dosage adjustments in the management of conditions like diabetes, pain, epilepsy, nausea, Parkinson’s disease, and chronic myeloid leukemia.

**ABCC5**: ABCC5, an efflux transporter gene, influences the pharmacokinetics and pharmacodynamics of several drugs, notably altering the bioavailability and systemic toxicity of doxorubicin, a key cancer chemotherapy drug. Other drugs such as glyburide, leucovorin, cannabidiol, irinotecan, and fluorouracil are also likely affected by ABCC5's capacity to modulate drug levels, either impacting their therapeutic efficacy or altering their toxicity profile.

**SLCO1B1**: The SLCO1B1 gene, which facilitates the hepatic uptake of drugs, exhibits polymorphisms like c.521T>C that affect the pharmacokinetics of multiple drugs including statins, repaglinide, and rifampin, potentially leading to increased drug plasma concentrations, altered efficacy, and toxicity. This variability in drug transport efficiency necessitates adjustments in dosing to optimize therapeutic outcomes and minimize adverse effects for drugs such as simvastatin, atorvastatin, and others.

**UGT2B17**: The gene UGT2B17 impacts the pharmacokinetics of drugs such as belzutifan, clopidogrel, and exemestane through its role in glucuronidation, influencing their elimination, efficacy, and potential interactions, particularly in individuals with gene variations that affect enzyme activity. This alters the drugs' absorption, metabolism, excretion, plasma concentrations, and overall effectiveness.

**CYP1A2**: CYP1A2 plays a pivotal role in the pharmacokinetics of drugs, influencing their metabolism and, consequently, efficacy and safety. This enzyme is responsible for processing medications such as clozapine, theophylline, caffeine, erlotinib, deferasirox, escitalopram, and clopidogrel, where genetic variability can significantly affect therapeutic outcomes and requires careful dosage adjustments to prevent toxicity or enhance drug effectiveness.

**DCK**: Deoxycytidine Kinase (DCK) is fundamental in the metabolism of anticancer drugs like gemcitabine and cytarabine, as variations in the DCK gene affect the transformation of these drugs into their active forms, pivotal for their effectiveness and potential resistance in cancer treatment. For gemcitabine and the ara-CTP metabolite of cytarabine, DCK facilitates their activation through phosphorylation processes, influencing drug efficacy and toxicity in treatments for cancers such as pancreatic, breast, non-small cell lung cancers, and leukemias.

**NR1I2**: NR1I2, or pregnane X receptor (PXR), regulates genes encoding drug-metabolizing enzymes and transport systems like CYP3A4 and MDR1, influencing the pharmacokinetics of various drugs. Activators of NR1I2 such as rifampin and carbamazepine can increase the metabolism and decrease the efficacy of drugs like sirolimus and rosuvastatin by upregulating CYP3A4, while inhibitors can slow metabolism, increasing toxicity risk.

**RUNDC3B**: Although the gene RUNDC3B is primarily involved in intracellular trafficking, its potential pharmacogenetic interaction with imatinib, a tyrosine kinase inhibitor used in cancer treatment, remains speculative. Given RUNDC3B's role in cellular dynamics, there is a possibility that it could influence the intracellular concentration and efficacy of imatinib in cancer cells, particularly those with varying expressions of RUNDC3B; however, this interaction lacks concrete evidence and is still under exploration.

**CYP26C1**: CYP26C1, responsible for retinoic acid metabolism, affects the pharmacokinetics of retinoids like isotretinoin and acitretin, where its genetic variations can alter drug metabolism, influencing their efficacy and safety. Increased CYP26C1 activity might reduce the effectiveness of these drugs by speeding up their metabolism, while decreased activity could increase drug toxicity by allowing higher drug concentrations in the body, suggesting a need for personalized dosing based on CYP26C1 genotype.

**COMT**: COMT (Catechol-O-Methyltransferase) influences the effectiveness and side effects of various drugs by metabolizing catecholamine neurotransmitters such as dopamine. Drugs like rasagiline and tolcapone used in Parkinson's disease directly interact with COMT, affecting dopamine levels; meanwhile, other medications such as antipsychotics, ADHD treatments, and opioids may also be affected by COMT activity variations, particularly due to genetic polymorphisms like Val158Met, impacting drug responses and necessity for dosage adjustments.

**NQO2**: NQO2, which is involved in metabolizing quinone-containing drugs like cytarabine, idarubicin, doxorubicin, and cyclophosphamide, influences their toxicity and therapeutic utility through complex pharmacokinetic and pharmacodynamic interactions. Inhibitors like imatinib and resveratrol affect NQO2 activity, potentially enhancing or altering the therapeutic effects of these drugs, especially in cancer therapy, by impacting their metabolism and effectiveness.

**MROH2A**: MROH2A is suspected to interact pharmacogenetically with drugs like acetaminophen and erlotinib; these interactions could potentially affect drug metabolism, toxicity, therapeutic levels, and treatment outcomes through modulation of cell signaling pathways or cellular integrity. However, the evidence supporting these interactions is speculative and not yet confirmed by extensive clinical or pharmacological studies.

**ABCC3**: The ABCC3 gene significantly influences the pharmacokinetics and pharmacodynamics of drugs such as methotrexate and morphine by affecting their transport. Variants in ABCC3 can lead to altered excretion of methotrexate, which affects its effectiveness and side effects, and can modify the transport of morphine and its metabolites, impacting their systemic and neurological effects. Other chemotherapy drugs like doxorubicin and vincristine may also interact with ABCC3, potentially influencing drug efficacy and resistance through effects on drug efflux.

**FMO5**: The FMO5 gene, unlike its family members, has a unique role in pharmacogenetics, particularly due to its broad substrate specificity and presence in the liver and small intestine. It indirectly influences drug metabolism, such as with metformin, by potentially altering the metabolic environment or modifying intermediate biomolecules, thus affecting the drug's efficacy and safety through non-traditional pathways related to its handling of metabolic byproducts connected to sulfur and nitrogen.

**GSTA3**: GSTA3, part of the glutathione S-transferase family, plays a critical role in detoxifying xenobiotics and drugs, particularly by enhancing the solubility and excretion of agents susceptible to conjugation with glutathione such as certain antineoplastic agents. This enzymatic activity could reduce the effectiveness of drugs like alkylating agents used in chemotherapy by accelerating their detoxification, impacting therapeutic outcomes.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**ABCC11**: The ABCC11 gene, known for facilitating ATP-dependent transport across cellular membranes, significantly affects the pharmacokinetics of anticancer drugs like fluorouracil and capecitabine by varying the efficiency of drug metabolite expulsion from cells. Different ABCC11 genetic variants lead to changes in drug bioavailability and toxicity, which affects the efficacy and side effects experienced by patients, making it pivotal for customizing cancer treatment protocols.

**SULT1E1**: SULT1E1 is critical in the pharmacogenetics of hormone-related treatments such as estrogen replacement therapies and hormonal contraceptives by sulfating and inactivating estrogens, which affects the efficacy and toxicity of these drugs. While not directly altering pharmacokinetics, SULT1E1's influence on estrogen metabolism suggests a potential non-pharmacokinetic interaction with methotrexate, particularly in hormone-dependent cancers, where estrogen pathways might intersect with methotrexate's anti-proliferative effects.

**ABCC10**: ABCC10, known as Multidrug Resistance Protein 7 (MRP7), plays a significant role in drug efflux, affecting the pharmacokinetics and potentially the pharmacodynamics of various drugs. This gene modulates the absorption and elimination of drugs like nevirapine and impacts drug resistance in chemotherapeutic agents such as docetaxel and oxaliplatin by enhancing their extrusion and reducing their intracellular accumulation. It also influences the disposition of antiviral agents like tenofovir, ultimately affecting their therapeutic efficacy and contributing to personalized medicine strategies by optimizing treatment based on individual genetic profiles.

**SLC22A16**: SLC22A16 plays a critical role in the pharmacokinetics of doxorubicin, a chemotherapeutic drug, by affecting its transport and thereby influencing the drug's efficacy and potential for cardiac toxicity. Although primarily involved with doxorubicin, SLC22A16 may also affect other chemotherapy drugs like fluorouracil and cyclophosphamide, potentially altering their metabolism or mechanisms of action rather than their transport.

**ABCB6**: ABCB6 mutations impact the pharmacokinetics of drugs like cyclophosphamide and doxorubicin by affecting their absorption into cells and intracellular storage, which influences the drugs’ effectiveness and toxicity. This variation in drug handling due to ABCB6 can significantly alter the therapeutic efficacy and side effects of these chemotherapeutic agents, underscoring the importance of genetic considerations in cancer treatment planning.
